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Abstract
Irisin is a myokine secreted by skeletal muscles. It has been proposed to drive the brown-fat-like conversion of the 
white adipose tissue. By enhancing energy expenditure, irisin may affect systemic metabolism and be associated 
with insulin resistance; however, the mechanism(s) of action still remain largely unexplained. The discovery of irisin 
can contribute to the exploration of the novel and effective therapeutic targets or therapeutic strategies of metabolic 
diseases or metabolism-associated health issues. In this review, based on the recent literature (from 2013 to 2015 
inclusive), we will systematically discuss the associations of irisin with obesity, type 2 diabetes, lipid disorders, and 
hypertension. We also introduce unanswered questions for future research.
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Background
Irisin, which has been extensively studied since 
2012, is a cleaved and secreted fragment of the type I 
membrane of fibronectin type III domain-containing 
protein 5 (FNDC5) and is mainly secreted from skel-
etal muscle in response to exercise. The myokine in-
duces browning of white adipose tissue and expends 
accumulated energy on the heat, and hence it was 
initially proposed to mediate the beneficial effects 
of exercising on energy metabolism and body com-
position. By this thermogenic effect, irisin improves 
metabolic profile of the adipose tissue and enhances 
whole-body energy expenditure. It was shown that 
on exercise stimulation, there is overexpression of 
FNDC5 (the precursor of irisin) in skeletal muscles, 
which acts as muscle-derived signal to the white adi-
pose tissue [1, 2]. As a result, irisin may promote in-
creased oxygen consumption and energy supply [3]. 
Indeed, many earlier studies demonstrated associ-
ation between intensive exercises and irisin levels. 
Norheim et al. [4] studied the group of 26 inactive 
men (pre-diabetic and non-diabetic), aged 40–65 
years, who were recruited for a 12-week intervention 
of combined endurance and strength training with 
four sessions of training per week. Before and after 
the 12-week intervention period, participants were 
exposed to an acute endurance workload of 45 min 
at 70% of VO2 max. They found a 1.2-fold increase 
in irsin levels shortly after acute endurance work-
loads; however, circulating irisin was reduced in re-
sponse to 12 weeks of combined training. A similar, 
transient, post-load increase in irisin concentration 
was also reported in healthy individuals undergoing 
moderate aerobic exercises [5]. The brief rise in irisin 
level after exercise suggests an acute shedding event 
of irisin during exercise.
In contrast to those studies, several investigations 
failed to confirm these findings [6–9]. Kerstholt et al. 
found in the population-based Study of Health in 
Pomerania (SHIP-TREND) an inverse association 
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between irisin serum concentration and exercise ca-
pacity assessed by peak VO2 and maximum power 
output but only in men. In contrast, in women, 
a trend towards a positive relationship between iri-
sin and peak VO2 was detected, whereas none of 
the other parameters showed significant associations 
with irisin [10]. Consistently, it was demonstrat-
ed that habitual runners had significantly healthier 
metabolic and body composition profiles compared 
with nonrunners; however, none of these favorable 
exercise effects were positively associated with circu-
lating irisin [11].
Notwithstanding these discrepancies in the liter-
ature, irisin has gained great interest as a potential 
new marker, as well as a target to combat obesity 
and obesity-related metabolic abnormalities [12]. 
The rationale for this suggestion has been support-
ed by experimental data. In the study of Saleem et 
al., C57Bl/6 mice were fed with high-fat diet for 
6 months until the animals were hyperglycemic and 
glucose intolerant. Then, intravenous injections of 
recombinant irisin were given for 8 weeks. Although 
treatment with irisin had no effect on fasting glucose 
levels or body weight, glucose tolerance in these ani-
mals significantly improved [13]. Other investigators 
described that central and peripheral irisin could 
differentially regulate cardiovascular activities. While 
administration of recombinant human irisin into 
the 3rd brain ventricle of rats activated neurons in 
the paraventricular nuclei of the hypothalamus with 
a subsequent increases in blood pressure (BP) and 
cardiac contractibility, peripheral administration of 
this myokine reduced BP in both control and spon-
taneously hypertensive rats [14]. The latter finding 
may be relevant in future investigations on potential 
therapeutic use of irisin in humans. However, studies 
evaluating the association of irisin with BP in hu-
mans are scarce.
Irisin and blood pressure
There have been only few reports evaluating the re-
lation between circulating irisin and BP in humans. In 
a cross-sectional study, Yan et al. collected data on so-
ciodemographic, lifestyle, and clinical characteristics 
from 1,115 community-living Chinese adults aged 
52.3 years with central obesity [15]. Of them, 57% 
had raised BP defined as systolic BP ≥ 130 mm Hg 
or diastolic BP ≥ 85 mm Hg or treatment of previous-
ly diagnosed hypertension. In this population, no sig-
nificant associations between irisin level and BP were 
found. A similar lack of correlation of irisin with BP was 
found in a cohort of nondiabetic adult subjects [16]. 
In another cross-sectional study, Brondani et al. [17] 
investigated the association of FNDC5 rs3480 (A/G) 
and rs1746661 (G/T) polymorphisms with clinical 
characteristics in 1,006 patients with type 2 diabetes 
(T2DM) and 434 nondiabetic subjects. They found 
that the T allele of rs1746661 was associated with in-
creased systolic BP and not diastolic BP, but only in 
women with diabetes. In contrast to these reports, in 
532 patients with stages 1−5 of chronic kidney dis-
ease, irisin positively correlated with diastolic BP but 
not systolic BP [18]. However, Park et al. [19] demon-
strated a positive correlation between irisin concen-
tration and both systolic BP (R = 0.17; P = 0.04) 
and diastolic BP (R = 0.27; P = 0.001) in healthy 
middle-age individuals. The discrepancies in the 
abovementioned reports may be due to different 
populations analyzed in the studies, as some includ-
ed subjects with metabolic diseases and wide ranges 
of BMI, which may influence baseline irisin levels. 
However, it is worth noting that to date none of the 
studies evaluated irisin levels in patients with essen-
tial hypertension and without coexisting diseases in 
comparison with normotensive subjects. Hence, in 
the light of promising results from rodent studies 
[14], clinical studies on irisin in patients with hyper-
tension are urgently needed. Much more is known 
about altered irisin performance in conditions that 
frequently coexist with hypertension such as obesity, 
T2DM, and dyslipidemia.
Irisin in obesity, diabetes and lipid 
disorders
It has been shown in rodent models that overex-
pression of irisin increases total body energy expendi-
ture, induces weight loss, and improves glucose toler-
ance and insulin sensitivity [20]. Moreover, in an ex-
perimental model, injected irisin alleviated endothe-
lial dysfunction in diabetic rats by reducing oxidative/
nitrative stress through inhibiting signaling pathways 
implicating PKC-b/NADPH oxidase and NF-kB/
iNOS [21], as well as ameliorated lipid derange-
ments via cAMP-PKA-HSL/perilipin pathway [22]. 
All together, these data suggest that irisin may be 
a promising molecule for the treatment of vascular 
complications and lipid disorders in T2DM.
In human studies, some evidence suggests an an-
tidiabetic role of irisin. It was demonstrated that 
irisin may improve glucose homoeostasis [23, 24] 
and show an inverse association with intrahepatic tri-
glyceride contents in obese [25]. However, contrary 
to these suggestions, obese individuals have been 
found to have higher circulating levels of irisin than 
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normal weight or anorexic patients [26, 27]. More-
over, higher irisin levels were also reported in indi-
viduals with metabolic syndrome (MetS) compared 
to those without MetS [19] as well as nondiabetic 
adults with insulin resistance and evidences of vascu-
lar atherosclerosis [16]. Reinforcing these findings, 
significant weight loss, either by calorie restricted diet 
or bariatric surgery, has been demonstrated to lower 
circulating irisin level, while the reduction of irisin 
after weight loss was reversed in those subjects who 
regained their original weight [28, 29]. On the other 
hand, some studies reported no correlation or de-
creased irisin levels in obese compared to non-obese 
individuals [30, 31] or even a negative correlation of 
irisin with body mass index (BMI) [32].
Despite these controversies, most studies demon-
strated a positive association of circulating irisin level 
with obesity suggesting that plasma irisin concentra-
tions reflect net body adiposity, which is in apparent 
conflict with the suggested anti-obesity effect of this 
myokine. A possible explanation which could recon-
cile the discrepant data may be that FNDC5/irisin 
in physiological conditions exert a protective effect 
against obesity mediated by the browning of white 
adipose tissue and is thus increased in compensation 
for increasing body mass. In states of severe obesity, 
irisin in physiological concentration is not capable 
to maintain the balance of energy storage and ener-
gy expenditure. In such situation, along with mus-
cle, irisin is also generated by adipose tissue [27], 
responding to direct alterations in body fat mass. 
Therefore, the increased circulating levels of irisin 
observed in obese patients may represent an adaptive 
response to counteract the metabolic disturbances 
associated with obesity [33, 34] and likely, when 
this adaptive mechanism fails, target tissues deve-
lop resistance to irisin. If confirmed, stimulation of 
irisin secretion or release through pharmacological 
strategies or use of irisin as a therapeutic agent could 
both prove ineffective, at least in extremely obese 
individuals.
Plasma irisin level in diabetes varies depending on 
the type of disease. There has been only one study 
demonstrating that in type 1 diabetes irisin level is 
increased [35], while in long-term [31, 37–40] and 
newly diagnosed T2DM [32, 36], and gestational 
diabetes it is frequently decreased in comparison 
with normal glucose tolerance (Table I). Assyov et 
al. in a well-designed study, demonstrated that cir-
culating irisin levels progressively decreased with the 
worsening of glucose tolerance: it was the highest 
in individuals with normal glucose tolerance (me-
dian value of 619 ng/ml; interquartile range (IQR) 
= 567 ng/ml), lower in prediabetes (314 ng/ml; IQR 
= 577 ng/ml) and the lowest in T2DM (228 ng/ml; 
IQR = 200 ng/ml) [40], suggesting that with progres-
sion of insulin resistance, plasma irisin levels dimin-
ish. On the other hand, although in their study, irisin 
correlated negatively with fasting glucose (R = − 0.547; 
p < 0.001), the authors showed a positive correlation 
between irisin and BMI (R = 0.475; p < 0.001).
Lowered values of irisin in T2DM may seem sur-
prising as subjects with this condition are frequently 
overweight or obese and therefore they rather should 
tend to have higher irisin levels. Additionally, they 
develop insulin resistance, which is also frequently 
associated with increased irisin levels [19]. A possible 
explanation of this paradox might be that the main 
source of circulating irisin in extremely obese sub-
jects without overt glucose dysregulation seems to be 
the adipose tissue and not skeletal muscles [27]. In 
turn, in nonobese to moderately obese patients with 
insulin resistance, irisin released from muscles might 
be downregulated due to muscle insulin resistance, 
although to date, studies have yielded ambiguous re-
sults. Recent reports have described a direct associa-
tion between irisin and insulin, alongside with an in-
verse correlation between irisin and ghrelin (orexigen-
ic hormone with an opposite action to insulin) [29], 
while intervention studies showed that after treat-
ment designed to lose weight, higher irisin concen-
trations at the beginning of the intervention were 
associated with greater reductions in glucose, insulin 
and irisin concentrations, and homoeostasis model 
assessment of insulin resistance (HOMA-IR) index, 
independent of body weight reduction [46]. Irisin 
was identified as a potential factor associated with 
progression of insulin resistance in patients who re-
Table I. Circulating irisin level in diabetes
Type of diabetes Irisin level Reference
Type 1 Increased Espes [35]
Long-term T2DM Decreased Moreno-Navarette [31]; Liu [37]; Zhang [38]; Duran [39]; Assyov [40]
Newly diagnosed T2DM Decreased Choi [32]; Xiang [36]
Gestational diabetes Decreased
No difference
Yuksel [41]; Kuzmicki [42]; Wawrusiewicz [43]; Zhao [44]
Ebert [45]
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gain their diet-induced weight loss [47]. Accordingly, 
a positive correlation has been found between base-
line irisin levels and insulin resistance, as assessed by 
HOMA-IR [19]. However, whether decreased irisin 
level in T2DM represents a true cause-effect relation-
ship remains unclear.
Irisin has also been tested as a marker of abnormal 
lipid profile, which gave unfavorable cardiovascular 
outcomes but results have been inconsistent [48–52]. 
Studies have shown either positive or negative associ-
ations of irisin with total cholesterol, high (HDL) and 
low density lipoproteins (LDL), and triglycerides (Ta-
ble II). Zhang et al. [25] found that serum irisin levels 
were reduced in obese adults with non-alcoholic fatty 
liver disease (NAFLD), progressively with the increase 
of intrahepatic triglyceride content. These findings 
strongly suggest that irisin may play an important role 
in lipid metabolism and the development of NALFD. 
In obese individuals with other cardiovascular risk 
factors, increased circulating irisin levels were found 
to be correlated with unfavorable lower HDL [51]. 
On the other hand, lower irisin level was an inde-
pendent predictor of macrovascular complications in 
T2DM [38] and similarly, in non-diabetic population 
— a robust predictor of unwilling cardiovascular out-
comes such as myocardial infarction [52].
Concluding remarks
Irisin has been primarily investigated as a key 
myokine, which has a bridging potential between 
muscle and fat. Growing evidence supports the hy-
pothesis that increased circulating irisin may reflect 
a compensatory response to impaired insulin sensi-
tivity and other metabolic disorders associated with 
obesity. However, the potentially beneficial effect 
of FNDC5/irisin in the treatment of hypertension 
and obesity-related metabolic deteriorations has been 
challenged by insufficient and contradictory findings. 
Albeit preliminary results of treatment with exoge-
nous irisin of hypertension and glucose intolerance 
in rodents are promising, it is too early to translate 
the effects observed in murine models to humans as 
they need to be confirmed in further studies aiming 
to (i) identify irisin receptor; (ii) understand the 
molecul ar pathways regulating irisin expression; and 
(iii) establish causality of this myokine in the deve-
lopment of metabolic diseases. In addition, as human 
FNDC5 is mainly translated from its non-canonical 
start codon, some recent reports even questioned the 
existence of circulating irisin and claimed that many 
human irisin antibodies used in commercial ELISA 
kit lack required specificity [1, 34].
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